Glaxo, Theravance Report Relovair Safety Data

From Associated Press (September 22, 2010)


NEW YORK -- GlaxoSmithKline PLC and Theravance Inc. said Wednesday their lung disease and asthma drug Relovair met its goals in a mid-stage safety study.

The companies said Relovair’s effects on heart function and the rate of side effects were similar to a placebo. Patients who took Relovair had larger improvements in lung function than patients who took the placebo, the companies said.

The trial involved 60 patients with a mean age of 64 years.

Relovair is a combination of the fluticasone -- the main ingredient in GlaxoSmithKline’s drug Advair -- and a second drug, vilanterol. The companies are running late stage clinical trials of Relovair as a treatment for asthma and chronic lung disease.

The drug is designed to be taken by inhaler once per day.

GlaxoSmithKline and Theravance said the most common side effects of Relovair and the placebo were nasal inflammation, headache, dizziness, and candidiasis. They said 68 percent of the Relovair patients and 50 percent of the placebo patients reported some side effects.

 

Posted: September 2010


View comments

Hide
(web3)